Amnon Schlegel

Amnon Schlegel, MD, PhD, serves as Medical Director in Global Clinical Development at Ultragenyx since April 2024, overseeing late-stage development and post-marketing surveillance for rare bone diseases. Concurrently, Amnon has held positions at the University of Utah School of Medicine since 2010, progressing to Adjunct Associate Professor while also being recognized with tenure as Associate Professor. Experienced in clinical and translational research focusing on fasting metabolism, diabetes mellitus, and lipid metabolism, Amnon has contributed to clinical trials in nonalcoholic fatty liver disease and obesity while working previously in significant medical roles at Terns Pharmaceuticals, Diabetes & Endocrine Treatment Specialists, the U.S. Department of Veterans Affairs, UCSF Medical Center, and Beth Israel Deaconess Medical Center. Amnon's educational background includes an Executive MBA from Quantic School of Business and Technology, an MD and PhD from Albert Einstein College of Medicine, and additional training from Harvard Medical School and the University of California, San Francisco.